成本和食管治疗(Cost and Esophageal Healing)_计算生物学_科研数据集

数据摘要：

One hundred and eighty-four patients were allocated to one of two treatments (Treat) for severe erosive esophagitis. The primary efficacy endpoint was the healing of all erosions as determined by endoscopy after four and eight weeks of therapy. Patients who healed at four weeks left the study and were assumed to still be healed at week 8. Cost data were also collected with respect to study drug and concomitant antacids as well as all non-protocol driven medical costs (i.e., physician visits, emergency room visits, treatment of adverse effects, procedures, etc.) from the prospective of a third party payor. Total costs are tabulated.

中文关键词：

成本,食管治疗,病人,治疗,分类,

英文关键词：

cost,esophageal healing,patient,treatment,classification,

数据格式：TEXT

数据用途：

The data can be used for computational biology.

数据详细介绍：

Favorite Datasets from Early (and Late) Phases of Drug Research

Cost and Esophageal Healing

Part 4 - Table 7

Abstract

One hundred and eighty-four patients were allocated to one of two treatments (Treat) for severe erosive esophagitis. The primary efficacy endpoint was the healing of all erosions as determined by endoscopy after four and eight weeks of therapy. Patients who healed at four weeks left the study and were assumed to still be healed at week 8. Cost data were also collected with respect to study drug and concomitant antacids as well as all non-protocol driven medical costs (i.e., physician visits, emergency room visits, treatment of adverse effects, procedures, etc.) from the prospective of a third party payor. Total costs are tabulated.∙Is the success of treatment influenced by baseline disease severity (Bs Sev)?

∙Is there a significant difference in efficacy between the two drugs?

∙Is there a significant difference in total cost between the two treatments?

∙What are the effects of skewness and outliers in the cost data?

∙What is the incremental cost-efficacy?

∙Is there evidence of a statistically significant difference between the two treatment in cost-efficacy?

(a) A higher rating indicates greater severity of disease.

(b) Each value represents an individual patient. Values were rounded to nearest dollar (1992 U.S.).

Source:

Bradstreet, T.E. and Liss, C.L. (1995) "Favorite Data Sets from Early (and Late) Phases of Drug Research - Part 4." Proceedings of the Section on Statistical Education of the American Statistical Association.

数据预览：

点此下载完整数据集